Ranibizumab
- Generic Name
- Ranibizumab
- Brand Names
- Byooviz, Cimerli, Lucentis, Susvimo, Ranivisio, Rimmyrah, Ximluci
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 347396-82-1
- Unique Ingredient Identifier
- ZL1R02VT79
- Background
Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular degeneration. Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovasc...
- Indication
Ranibizumab injection for intravitreal use is indicated to treat Neovascular (wet) Age-related Macular Degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
...
- Associated Conditions
- Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD)
- Associated Therapies
- -
Head to Head Study of Anti-VEGF Treatment.
- Conditions
- Interventions
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2017-11-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT02577107
- Locations
- šØš³
Novartis Investigative Site, Chengdu, Sichuan, China
Study of DS-7080a for the Treatment of Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2015-08-21
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 56
- Registration Number
- NCT02530918
Retinal Sensitivity in BRVO After Anti-VEGF Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-08-19
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Fukushima Medical University
- Target Recruit Count
- 50
- Registration Number
- NCT02527733
- Locations
- šÆšµ
Department of Ophthalmology, Fukushima Medical University, Fukushima, Japan
Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas
- Conditions
- Interventions
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- PD. Dr. med. Armin Wolf
- Target Recruit Count
- 60
- Registration Number
- NCT02522897
Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2015-07-30
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- Ohr Pharmaceutical Inc.
- Registration Number
- NCT02511613
- Locations
- šŗšø
Investigational Site, Houston, Texas, United States
Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study
- First Posted Date
- 2015-07-29
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- University of Nebraska
- Registration Number
- NCT02511067
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
- First Posted Date
- 2015-07-29
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 225
- Registration Number
- NCT02510794
- Locations
- šŗšø
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
šŗšøN CA Retina Vitreous Assoc, Mountain View, California, United States
šŗšøRetina Research Center, Austin, Texas, United States
A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
- Conditions
- Interventions
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 273
- Registration Number
- NCT02484690
- Locations
- šŗšø
Retina Consultants, San Diego, Poway, California, United States
šŗšøNew England Retina Associates, Hamden, Connecticut, United States
šŗšøAustin Retina Associates, Austin, Texas, United States
Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Nagoya City University
- Target Recruit Count
- 27
- Registration Number
- NCT02478515
- Locations
- šÆšµ
Nagoya City Univsersity, Nagoya, Aichi, Japan
To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2016-04-19
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 60
- Registration Number
- NCT02462304
- Locations
- šØš³
The University of Hong Kong, Hong Kong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.